Medical Technology M&A Pulse – Q1 2021

2021: Hope On The Horizon

• For millions of Americans and others around the world who have received a COVID-19 vaccine, reassuring signs of hope have begun to emerge. As of the time of publication, just under half of Americans have received at least one dose, with over 44% fully vaccinated. A rollout of this speed is monumental, with over 300 million doses administered to date.
• This effort was enabled by partnerships between the public and private sector, with healthcare companies of all types playing a role. The rollout of the vaccine in the U.S. was largely successful, with doses administered skyrocketing during February, March, and April, with the percentage of Americans who received at least one dose climbing from 7.9% February 1, to 44.1% by April 30. Recently however, vaccinations have plateaued in some areas, and these pockets are seeing rising COVID cases. Nevertheless, the rapid development and rollout of COVID-19 should be considered one of the most impactful public health achievements in decades, with innumerable lives saved and the potential for life to return to normalcy now conceivable.
• During the year to date, PMCF’s four Medical Technology indices have generally followed the performance trends of the benchmark S&P 500 Growth Index and Dow Jones Industrial Average, though they lagged behind the Dow’s robust performance during March and April.

Read Medical Technology M&A Pulse Q1 2021 Full Report

Download



Preview